Scotia Capital
NGEN icon

Scotia Capital’s NervGen Pharma NGEN Stock Holding History

Scotia Capital’s Portfolio NGEN Stock Details NGEN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$25.2K Buy
13,240
+500
+4% +$958 ﹤0.01% 970
2026
Q2 		$26.3K Sell
12,740
-258
-2% -$801 ﹤0.01% 904
2026
Q1 		$49.1K Buy
+12,998
New +$56.3K ﹤0.01% 897

Other funds holding NGEN

Valley Forge Investment Consultants
Valley Forge Investment Consultants Audubon, Pennsylvania $405M AUM 13.69% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Bank of Montreal
Bank of Montreal Toronto, Ontario, Canada $313B AUM 26.62% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $77B AUM 19.24% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return
Moors & Cabot
Moors & Cabot Boston, Massachusetts $2.65B AUM 29.91% 1-Year Est. Return
Great Valley Advisor Group
Great Valley Advisor Group Wilmington, Delaware $6.91B AUM 16.83% 1-Year Est. Return
McKinley Carter Wealth Services
McKinley Carter Wealth Services Wheeling, West Virginia $1.96B AUM 13.62% 1-Year Est. Return
Traynor Capital Management
Traynor Capital Management Malvern, Pennsylvania $2.17B AUM 49.17% 1-Year Est. Return

Scotia Capital's NGEN Position: Q3 2026 in Review

Scotia Capital increased its NervGen Pharma (NGEN) stake by 3.9% in Q3 2026, buying an estimated $958 and bringing the position to 13,240 shares worth $25.2K. The position accounts for ﹤0.01% of the portfolio, ranked #970.

Scotia Capital first reported a position in NGEN in Q1 2026 and has held it in 3 quarters since. The position peaked at $49.1K in Q1 2026. 28 funds tracked by Wall St. Rank hold NGEN as of Q3 2026.

  • Scotia Capital held 13,240 shares of NervGen Pharma worth $25.2K as of Q3 2026.
  • Scotia Capital bought 500 NervGen Pharma shares in Q3 2026, an estimated $958.
  • NervGen Pharma made up ﹤0.01% of Scotia Capital's portfolio in Q3 2026, its #970 holding.
  • Scotia Capital first reported a position in NervGen Pharma in Q1 2026 and has held it in 3 quarters since.
  • Scotia Capital's NervGen Pharma position peaked at $49.1K in Q1 2026.
  • 28 funds tracked by Wall St. Rank held NervGen Pharma as of Q3 2026.

Based on Scotia Capital's 13F filing for Q3 2026, filed 10 Nov 2026.